COVID-19

Jeffery Goad, PharmD, MPH, associate dean of Academic Affairs in School of Pharmacy at Chapman University discusses the future of pharmacy when it comes to immunizations.

Moderna seeks EUA for its Spikevax COVID-19 vaccine for a fourth booster dose in individuals 18 years of age and older who have received an initial booster of any authorized or approved COVID-19 vaccine.

Michele Belcher, president of the National Community Pharmacists Association, and pharmacist and pharmacy owner at Grants Pass Pharmacy, discusses ways of transforming the pharmacy profession’s current challenges into opportunities for positive change for the profession.

Investigators call for routine monitoring of vaccination effectiveness as the pandemic continues to evolve.

Pfizer Inc and BioNTech seek approval for an additional fourth booster dose of their COVID-19 vaccine for adults 65 years of age and older who received an initial booster of any of the authorized or approved COVID-19 vaccines.

The medication is the first oral therapy specifically to treat the virus evaluated in a pediatric clinical trial.

These individuals, who were also more likely to require treatment in the intensive care unit, should get their vaccines and booster shots, investigators say.

Despite early excitement about the potential for pharmacists to prescribe COVID-19 oral antivirals, the program does not provide that ability.

Investigators advise third short for patients with weakened immune system, especially organ transplant recipients.

Effectiveness is estimated at approximately 91% against any SARS-CoV-2 infection and approximately 85% effective against asymptomatic infection, analysis results show.

Experts David Pope, PharmD, and Christina Madison, PharmD, FCCP, AAHIVP, discussed the Biden Administration's new test-to-treat plan.

Study results show immunoglobulin G antibodies were detected in 13 of 382 individuals in the first phase and 71 of 168 in the second, with age and vaccination status contributing factors.

Investigators at Penn State find that these medications inhibit certain viral enzymes called proteases that are essential for SARS-CoV-2 replication in infected human cells.

COVID-19 vaccines are effective in preventing severe infection resulting in hospitalization, but protection wanes after 6 months.

Although biologic changes may occur in the body that affect the brain, nonbiologic changes, such as social isolation, can also be a part of it but the reasons are not completely clear, according to the study.

As we head into March, things appear to be looking up on the COVID-19 front.

During 90 minutes of exercise, the participants focused on maintaining a pace that kept their heart race approximately 120-140 beats per minute rather than focusing on the distance.

The results of 2 analyses in the United Kingdom show a small increase in the potential for intracranial thrombosis after vaccination.

Patients from more socially vulnerable areas were sicker when they arrived at hospitals but did as well as others by the time of discharge, results of a new analysis show.

How would you respond to these patient questions?

Institute for safe medication practices receives hundreds of reports of incorrect doses for children.

Findings of the study, published in International Immunopharmacology, also show that timing and patient selection is an important factor when administering intravenous immunoglobin.

Results of the analysis may help inform future COVID-19 vaccine development, investigators say.

During the period in which Omicron was the dominant variant, the researchers found that fewer patients died while hospitalized compared with those admitted when the Delta variant was dominant.

Jeff Trinkl, MD, director of clinical informatics at Epic, and Caleb Cox, data scientist at Epic, explain that only about 1.8% of patients contracted COVID-19 during a hospital stay at the highest peak of cases in December 2020.